Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Operating Expenses (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Operating Expenses for 5 consecutive years, with $69.6 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 76.6% to $69.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $263.7 million through Dec 2025, up 185.94% year-over-year, with the annual reading at $263.7 million for FY2025, 185.94% up from the prior year.
  • Operating Expenses hit $69.6 million in Q4 2025 for ARS Pharmaceuticals, down from $85.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $85.7 million in Q3 2025 to a low of -$41.1 million in Q4 2021.
  • Historically, Operating Expenses has averaged $24.3 million across 5 years, with a median of $18.8 million in 2021.
  • Biggest five-year swings in Operating Expenses: crashed 72.22% in 2022 and later skyrocketed 299.82% in 2025.
  • Year by year, Operating Expenses stood at -$41.1 million in 2021, then skyrocketed by 137.56% to $15.4 million in 2022, then crashed by 33.78% to $10.2 million in 2023, then skyrocketed by 285.14% to $39.4 million in 2024, then soared by 76.6% to $69.6 million in 2025.
  • Business Quant data shows Operating Expenses for SPRY at $69.6 million in Q4 2025, $85.7 million in Q3 2025, and $63.3 million in Q2 2025.